Cancer vaccines are a promising immunotherapeutic area, particularly in the field of prostate cancer. Here, Neal Shore, MD, of Carolina Urologic Research Center, Myrtle Beach, SC, discusses a clinical trial (NCT02514213) evalutating DNA vaccines, INO-5150 alone or with INO-9012, in biochemically relapsed prostate cancer. Dr Shore covers the method of administration, targets of the vaccine and the result observed, highlighting the reasons for his excitement about the potential of this treatment. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
Evaluation of a DNA vaccine for prostate cancer
